GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Synageva BioPharma Corp's quarterly accounts payable & accrued expense increased from Sep. 2014 ($22.44 Mil) to Dec. 2014 ($24.34 Mil) and increased from Dec. 2014 ($24.34 Mil) to Mar. 2015 ($26.88 Mil).
Synageva BioPharma Corp's annual accounts payable & accrued expense increased from Dec. 2012 ($7.69 Mil) to Dec. 2013 ($13.55 Mil) and increased from Dec. 2013 ($13.55 Mil) to Dec. 2014 ($24.34 Mil).
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Synageva BioPharma Corp Annual Data
|Accounts Payable & Accrued Expense||6.36||6.79||6.17||3.28||5.75||1.57||6.06||7.69||13.55||24.34|
Synageva BioPharma Corp Quarterly Data
|Accounts Payable & Accrued Expense||7.69||8.18||10.50||11.69||13.55||16.44||26.63||22.44||24.34||26.88|